Please login to the form below
Horizant
This page shows the latest Horizant news and features for those working in and with pharma, biotech and healthcare.
US shortage of GSK’s restless legs syndrome treatment Horizant
US shortage of GSK’ s restless legs syndrome treatment Horizant. FDA blames contract manufacturer delays. ... Then in November 2012, GSK and XenoPort agreed to end their collaboration, with all rights returned to Horizant's inventors XenoPort.
Latest news
-
GSK and XenoPort end restless legs syndrome collaboration
GSK and XenoPort end restless legs syndrome collaboration. Follows tough approval period for Horizant and subsequent poor sales . ... GlaxoSmithKline (GSK) has ended its collaboration with XenoPort to commercialise the restless legs syndrome drug
-
Horizant gets post-shingles pain indication in US
Horizant gets post-shingles pain indication in US. FDA approval comes as XenoPort and partner GlaxoSmithKline remain in dispute over commercial activities to promote drug. ... XenoPort and partner GlaxoSmithKline have won approval to extend the
-
GSK sales fall for first quarter of 2011
Recent approvals for GSK include lupus drug Benlysta (belimumab), Horizant (gabapentin enacarbil) for Restless Legs Syndrome and epilepsy treatment Trobalt (retigabine).
-
GSK Restless Legs Syndrome drug approved
GSK Restless Legs Syndrome drug approved. GlaxoSmithKline and XenoPort have won marketing approval from the US Food and Drug Administration for Horizant, a treatment for moderate-to-severe primary Restless Legs ... Horizant's approval for the condition
-
FDA rejects GSK and Xenoport's Horizant
The two companies submitted a New Drug Application (NDA) for Horizant extended-release tablets, to the FDA in January 2009. ... Horizant is developed from a variant of Pfizer's Nerontin (gabentin), used to control seizures in epilepsy patients.
More from news
Approximately 2 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
Deal Watch May 2016
399-616. Xenoport/ Arbor Pharmaceuticals. Corporate acquisition. Acquisition for $7.03 per share [60% premium]; includes Horizant [gabapentin] for restless legs.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
XenoPort appoints chief medical officer
Dr Kim has been with the US biopharma company since July 2013, when he joined as VP of medical affair, supporting the marketing of Horizant (gabapentin enacarbil) in restless legs syndrome
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
- Business Unit Head, Medical Communications, London
-
Excellent package
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
-
Senior Account Manager
-
Competitive salary commensurate with experience
Subscribe to our email news alerts
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- Moving annual total (MAT)
- MaxCyte gets green light for solid tumour cell therapy
- Brexit rebels win vote on European Medicines Agency alignment
- Positive mid-stage trial gives Allergy’s investors some welcome relief
- Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPO
- Ashfield Meetings & Events welcomes largest intake of students in seventh year of undergraduate placement scheme
- AstraZeneca joins Merck in Brexit stockpiling effort
- Vyriad inks immunotherapy alliance with Merck/Pfizer
- Huntsworth buys Giant Creative Strategy
- Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator
PMHub
SEVEN STONES
Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
